Search filters

List of works by Ferry Eskens

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors ⬇️

scientific article published on November 17, 2012

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

scientific article published on 31 March 2017

A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours

scientific article

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

scientific article published on 15 January 2008

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors

scientific article published in April 2004

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

scientific article

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

scientific article

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

scientific article

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

scientific article published on January 2004

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.

scientific article

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

scientific article published on 11 July 2016

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors ⬇️

scientific article published on October 5, 2011

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

scientific article published on 02 May 2013

Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned

scientific article published on 25 January 2018

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

scientific article published in May 2000

Clinical trial design for target specific anticancer agents

scientific article

Critical assessment of angiogenesis inhibitors in clinical trials

scientific article published in November 2002

Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept

scientific article published on 28 February 2013

Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents

scientific article published on November 17, 2001

Differentiation and definition of vascular-targeted therapies.

scientific article

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

scientific article published in May 2002

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

scientific article published in February 2000

Evaluation of patient enrollment in oncology phase I clinical trials.

scientific article

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study

Farnesyl transferase inhibitors: current developments and future perspectives

scientific article published in October 2000

Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006

scientific article published in March 2009

Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers

scientific article

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

scientific article

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

scientific article

Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives ⬇️

scientific article published on January 1, 2001

Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design ⬇️

scientific article published on February 16, 2012

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

scientific article

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study

scientific article

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

scientific article

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

scientific article published in January 2005

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

scientific article published in April 2004

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

scientific article published in February 2005

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

scientific article

Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer

scientific article published in March 2004

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

scientific article

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours ⬇️

scientific article published on September 7, 2010

Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group

scientific article published in May 2000

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

scientific article published on 27 July 2009

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

scientific article published on 21 March 2014

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

scientific article published on 21 September 2009

Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

scientific article

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

scientific article

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

scientific article

Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.

scientific article published in August 1999

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

scientific article published in September 2006

Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study

scientific article published on 15 October 2018

Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma ⬇️

scientific article published on February 1, 2011

Structure, Development, Preclinical and Clinical Efficacy of Tivozanib (KRN-951, AV-951) ⬇️

scientific article published on January 1, 2013

Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.

scientific article

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

scientific article

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial ⬇️

scientific article published on August 18, 2010

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

scientific article published on 5 March 2015

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

scientific article published on 13 November 2006

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

scientific article published on 11 September 2008

Vascular disrupting agents in clinical development

scientific article published on 20 March 2007

Paulina is supported by:

About Paulina

Help